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Background: To determine generic utilities for Spanish chronic obstructive pulmonary disease (COPD) patients
stratified by different classifications: GOLD 2007, GOLD 2013, GesEPOC 2012 and BODEx index.
Methods: Multicentre, observational, cross-sectional study. Patients were aged ≥40 years, with spirometrically
confirmed COPD. Utility values were derived from EQ-5D-3 L. Means, standard deviations (SD), medians and interquartile
ranges (IQR) were computed based on the different classifications. Differences in median utilities between groups were
assessed by non-parametric tests.
Results: 346 patients were included, of which 85.5% were male with a mean age of 67.9 (SD = 9.7) years and a mean
duration of COPD of 7.6 (SD = 5.8) years; 80.3% were ex-smokers and the mean smoking history was 54.2 (SD = 33.2)
pack-years. Median utilities (IQR) by GOLD 2007 were 0.87 (0.22) for moderate; 0.80 (0.26) for severe and 0.67 (0.42) for
very-severe patients (p < 0.001 for all comparisons). Median utilities by GOLD 2013 were group A: 1.0 (0.09); group B:
0.87 (0.13); group C: 1.0 (0.16); group D: 0.74 (0.29); comparisons were statistically significant (p < 0.001) except A vs C.
Median utilities by GesEPOC phenotypes were 0.84 (0.33) for non exacerbator; 0.80 (0.26) for COPD-asthma overlap;
0.71 (0.62) for exacerbator with emphysema; 0.72 (0.57) for exacerbator with chronic bronchitis (p < 0.001). Comparisons
between patients with or without exacerbations and between patients with COPD-asthma overlap and exacerbator
with chronic bronchitis were statistically-significant (p < 0.001). Median utilities by BODEx index were: group 0–2: 0.89
(0.20); group 3–4: 0.80 (0.27); group 5–6: 0.67 (0.29); group 7–9: 0.41 (0.31). All comparisons were significant (p < 0.001)
except between groups 3–4 and 5–6.
Conclusion: Irrespective of the classification used utilities were associated to disease severity. Some clinical phenotypes
were associated with worse utilities, probably related to a higher frequency of exacerbations. GOLD 2007 guidelines
and BODEx index better discriminated patients with a worse health status than GOLD 2013 guidelines, while GOLD
2013 guidelines were better able to identify a smaller group of patients with the best health.
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Chronic obstructive pulmonary disease (COPD) is a highly-
prevalent, progressive respiratory disease and a major
cause of morbidity and mortality worldwide [1]. Up to
10.2% of adults aged 40–80 years are affected by COPD in
Spain [2] and individuals with COPD experience significant
impairments in health-related quality of life (HRQL) [3].
There is interest in classifying the severity of COPD in
order to tailor diagnostic and therapeutic interventions.
In 2007, the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) [4] proposed a patient stratifica-
tion based on the severity of airflow limitation, as
measured by forced expiratory volume in 1 second, per-
centage of predicted (FEV1(%)). However, airflow ob-
struction is only one aspect of COPD, as there are other
aspects like reduced muscle strength, dyspnoea or func-
tional impairment in daily activities that are key compo-
nents of the health status of COPD patients. For this
reason, GOLD 2013 update [5] proposed a combined as-
sessment of COPD severity including lung function, the
history of exacerbations and the presence of symptoms.
Likewise, in 2012, in recognition of the heterogeneity of
COPD, the Spanish Society of Pulmonology and Thor-
acic Surgery, together with the scientific societies in-
volved in the health care of COPD patients, produced
new clinical practice guidelines (GesEPOC) [6] based on
the clinical phenotypes of COPD and proposed a COPD
severity classification based on the BODEx index.
Health utility is a measurement of preference that
shows the value placed on different health states over a
specific period. It is generally measured on a scale of 0–
1, with 0 being the worst possible (death) and 1 the best
possible health status [7]. Health utilities are widely used
in health economics as they provide information for clini-
cians, managers and other decision makers on the prefer-
ences given to certain health states. Health utilities also
allow measuring the benefits of health interventions in
terms of quality-adjusted life years, and they constitute an
essential parameter in cost-utility (CU) analyses, which
are the recommended type of economic evaluation [8,9].
In daily clinical practice, the most common instru-
ments for estimating health utilities are preference-based
generic HRQL questionnaires, of which the EuroQol-5D
(EQ-5D) [10] is the most-widely used. Furthermore, EQ-
5D questionnaire is recommended by health technology
assessment bodies like the National Institute for Health
and Care Excellence.
Various international [11-14] and Spanish [2,15-18]
studies have estimated the utility of COPD patients.
However, until now, no study had compared utilities in
the same population of COPD patients classified accord-
ing to different staging systems.
The aim of this study was to determine, using EQ-5D
3 levels (EQ-5D-3 L) questionnaire, health utilities inSpanish COPD patients stratified according to different
severity classifications. Primary analysis was performed
according to GOLD 2007. Secondary analysis included
GOLD 2013, GesEPOC 2012 (phenotypes and BODEx)
classifications.
Methods
Multicentre, observational, cross-sectional study includ-
ing patients recruited from 15 Spanish hospitals. The
study was approved by the Clinical Research and Ethics
Committee of Hospital Clinic (Barcelona, Spain) and all
patients gave written informed consent to participate.
Study population
Patients of both sexes, aged ≥40 years, with a diagnosis
of COPD of >12 months confirmed by spirometry (post
bronchodilator FEV1/FVC < 0.70 and FEV1 < 80%) were
included. All patients who attended to a scheduled out-
patient visit and fulfilled the inclusion/exclusion criteria
were recruited consecutively by the investigator of each
centre until the number of patients necessary for each
stratum had been completed. Patients had to be on
stable state without any exacerbation or hospitalization
in the previous 2 months. Patients with other respiratory
disease, advanced cancer (without possibility of remis-
sion), terminal patients or receiving palliative care, and
patients with cognitive impairment unable to understand
or complete the informed consent form and question-
naires, were excluded.
Sample size was estimated for the primary objective of
the study and was powered to detect differences in
health utilities in COPD patients stratified by lung func-
tion impairment: moderate, severe, and very-severe
(GOLD 2007) [4]. In order to detect a minimum clinic-
ally relevant difference in means of 0.1 points in health
utilities [19,20] between two groups of patients (moder-
ate vs. very-severe and severe vs. very-severe) and as-
suming a standard deviation (SD) of 0.26 points [11], at
least 128 patients per group would be required (95% re-
liability, 90% power, one-sided test, 10% dropout rate).
Due to the lower prevalence of very-severe patients,
which made recruitment difficult, sample size was recal-
culated to obtain the minimum number of very-severe
patients needed to achieve a statistical power of 80%.
After this new calculation, 68 very-severe patients were
required, assuming a sample size of 128 patients with
moderate and 128 with severe COPD (95% reliability,
one-sided test, 10% dropout rate).
Data collection and measurements
The main demographic and clinical variables, including
the clinical phenotype, were collected using a case report
form (CRF) specifically designed for the study.
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were obtained from spirometric testing (last measure-
ment performed in the previous 12 months or, if not
available, performed during the inclusion visit).
Comorbidities were evaluated by the Charlson comor-
bidity index [21], which predicts 10-year mortality for a
patient who may have a range of comorbid conditions.
Each condition is assigned a score (1, 2, 3 or 6) depend-
ing on the associated risk of death.
In addition, each patient completed the EQ-5D-3 L
questionnaire as well as the COPD Assessment Test
(CAT) [22] and the modified Medical Research Council
Dyspnoea Scale (mMRC) [23], both required for GOLD
2013 classification.
EQ-5D-3 L is a preference-based generic HRQL ques-
tionnaire consisting of 5 dimensions relating to health
(mobility, self-care, usual activities, pain/discomfort and
anxiety/depression) and ranges between 5 and 15. Each
dimension is divided into three levels of functioning (no
problems, some problems and extreme problems). Re-
spondents are asked to describe their health status by
ticking off one level of functioning for each of the five
dimensions, generating up to 243 different health states.
The questionnaire also includes a Visual Analogue Scale
(VAS) in which respondents are asked to value their
overall health status on a scale from 0 (worst imaginable
health state) to 100 (best imaginable health state).
CAT is a COPD-specific questionnaire that measures
the impact of the disease on HRQL and allows symp-
toms to be described. It evaluates the following symp-
toms: ongoing cough, breathlessness, wheezing, chest
tightness, impairment in daily activities, confidence,
quality of sleep and energy. CAT score ranges from 0 to
40, with 0 representing the lowest impact on HRQL and
40 the maximum impact.
mMRC measures the impact of dyspnoea on the activ-
ities of daily living. The score ranges from 0 (no dys-
pnoea) to 4 (dyspnoea preventing the patient leaving
home or which appears with activities such as dressing
or undressing).
Patients were stratified according to the phenotype or
severity criteria listed in clinical guidelines:
– GOLD 2007 [4]: Severity was determined according
to the post-bronchodilator FEV1 using the following
criteria: moderate, 50% ≤ FEV1 < 80% predicted;
severe, 30% ≤ FEV1 < 50% predicted; and very-severe,
FEV1 < 30% predicted.
– GOLD 2013 [5]: COPD patients were categorized in
four groups depending on the level of risk and
symptoms: A (low risk, fewer symptoms), B (low
risk, more symptoms), C (high risk, fewer
symptoms) D (high risk, more symptoms). Risk was
assessed according to the spirometric classification(high risk: severe and very-severe) and/or total
exacerbations in the past year (high risk: ≥ 2
exacerbations). In addition, patients with ≥1
hospitalizations for COPD exacerbations were
considered high risk. Symptoms were assessed
according to mMRC and CAT. In case of discrepancy
between mMRC and CAT results, the highest level of
severity was chosen. However, a sensitivity analysis
was performed by classifying patients using only CAT
or using only mMRC.
– Clinical phenotypes [6]: Phenotype characterization
was collected in the corresponding CRFs according
to GesEPOC criteria: non exacerbator phenotype,
corresponding to patients with less than 2
exacerbations the previous year; COPD-asthma
overlap phenotype or patients with a previous
diagnosis of asthma or some characteristics of
asthma, such as very positive bronchodilator test,
high serum IgE levels, increased blood eosinophilia
and others according to a consensus criteria recently
published [24]; exacerbator with emphysema
phenotype or patients with 2 or more exacerbations
the previous year and diagnosed with clinical/
radiological/functional emphysema; and exacerbator
with chronic bronchitis phenotype or patients with
2 or more exacerbations the previous year and
chronic cough and sputum production.
– BODEx index [25]: This multidimensional scale
categorizes patients in four levels from lesser to
greater severity (0–2, 3–4, 5–6 and 7–9) according
to BMI, FEV1 (%) post-bronchodilator, severe
exacerbations and mMRC score values.
Statistical analysis
Descriptive statistics included means, SD, medians and
interquartile ranges (IQR) for continuous variables and ab-
solute frequencies and percentages for discrete variables.
Health utilities were derived from EQ-5D-3 L scores
by applying weighted Spanish societal preferences [26]
to EQ-5D patient scores according to the following
formula:
Utility ¼ 1 ‐ 0:024 ‐ 0:106 : Mobility ¼ 2ð Þ ‐ 0:430
: Mobility ¼ 3ð Þ ‐ 0:134 : Self‐care ¼ 2ð Þ
‐ 0:309 : Self‐care ¼ 3ð Þ ‐ 0:071: Activity ¼ 2ð Þ
‐ 0:195 : Activity ¼ 3ð Þ ‐ 0:089 : Pain ¼ 2ð Þ
‐ 0:261 : Pain ¼ 3ð Þ ‐ 0:062 : Anxiety ¼ 2ð Þ
‐ 0:144 : Anxiety ¼ 3ð Þ ‐ 0:291
: if at least one answer is 3ð Þ þ 0:024
: if all answers are 1ð Þ:
Descriptive analysis of health utilities were calculated for
the different groups defined. Differences between groups
were assessed using non-parametric tests (Kruskal-Wallis,
Mann–Whitney U) due to the negative asymmetry shown
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hoc comparisons were performed using the Bonferroni
correction for multiple testing. Statistical significance was
established as alpha = 0.05 for all analyses. R version 3.0.2
statistical package [28] was used.
Results
A total of 358 patients were recruited, of whom 346 met
all the selection criteria and were included in the final
analysis.
Patients were 85.5% male, with a mean age of 67.9
(SD = 9.7) years and a mean duration of COPD of 7.6
(SD = 5.8) years; 80.3% were ex-smokers and the mean
smoking history was 54.2 (SD = 33.2) pack-years. Mean
post bronchodilator FEV1 (%) was 46.2% (SD = 12.1%).
The most frequent comorbidities were cardiovascular
diseases (27.2%) and diabetes (16.5%). The mean Charlson
index was 1 (SD = 1.4). In the previous 12 months, 58.4%
of patients had suffered at least one exacerbation, with a
mean of 1.3 (SD = 1.5) exacerbations. Mean scores for
CAT, mMRC and BODEx index were 16.2 (SD = 7.8), 1.8
(SD = 1.1), and 2.9 (SD = 1.9), respectively (Table 1).
Table 2 shows the cross-tabulated distribution of patients
according to the different classifications used. GOLD 2013
guidelines could differentiate patients with moderate
COPD, while the BODEx index differentiated better pa-
tients with severe or very-severe COPD. GesEPOC pheno-
types differentiated between COPD patients regardless of
their GOLD 2007 classification.
Determination of health utilities
According to EQ-5D-3 L results, the most frequent pro-
file was a COPD patient with some problems in walking
(53.2%), no problems in self-care (71.1%), no problems
in performing usual activities (58.1%), without pain or
discomfort (69.7%), and without symptoms of anxiety or
depression (57.5%). EQ-5D mean total score was 7.2
(SD = 2.0), and the mean VAS score was 59.1 (SD = 18.5)
(Table 3).
The mean value of EQ-5D health utilities was 0.73
(SD = 0.29), and the median was 0.81 (IQR = 0.26). The
health utilities obtained showed substantial negative
asymmetry (ceiling effect). The percentage of patients
with the highest-possible utility was 22%. This percentage
decreased with increasing disease severity (29.6% in pa-
tients with moderate COPD, 20% in patients with severe
COPD and 10.6% in patients with very-severe COPD).
Utilities according to GOLD 2007
135 (39.0%) moderate, 145 (41.9%) severe and 66 (19.1%)
very-severe patients were included. Stratified analysis of
health utilities according to pulmonary function showed
significant differences between the three groups (Table 4and Figure 1). There was a significant trend to lower
health utilities as pulmonary function declined.
Utilities according to GOLD 2013
28 (8.1%) patients were classified in group A, 66 (19.1%)
in group B, 30 (8.7%) in group C and 222 (64.2%) in
group D. Patients with more symptoms presented lower
utility values, with patients in group D having the lowest
utility. All pairwise comparisons were significant, except
for the comparison between groups A and C, maybe as a
consequence of a lack of statistical power for this com-
parison (Table 4 and Figure 2).
GOLD 2013 guidelines recommend the use of CAT or
mMRC for assessing symptoms. However, discrepancies
were detected in the GOLD 2013 classification depend-
ing whether CAT or mMRC scores were used. There-
fore, a sensitivity analysis was performed by classifying
patients using only CAT or using only mMRC. As in the
base case, both analyses showed significant differences
in the utility values between groups. Nevertheless, when
using only mMRC scale to obtain GOLD 2013 classifica-
tion, no statistical differences between B and D groups
were found (Table 5).
Utilities according to clinical phenotypes
In 24 cases no phenotype classification was provided by
the investigator. Among the 322 patients analysed, 207
(64.3%) were classified as non exacerbator, 21 (6.5%) as
COPD-asthma overlap, 41 (12.7%) as exacerbator with
emphysema and 53 (16.5%) as exacerbator with chronic
bronchitis (Table 4 and Figure 3). The global test
showed significant differences (p < 0.001) due to differ-
ences between patients with or without exacerbations
and between patients with COPD-asthma overlap and
those with exacerbations and chronic bronchitis.
Utilities according to BODEx index
167 (48.3%) patients were classified in the lower severity
group (0–2), 93 (26.9%) in the 3–4 interval group, 75
(21.7%) in the 5–6 interval group and 11 (3.2%) in the
most severe group (7–9). More severe patients presented
lower utility values (p < 0.001). All pairwise comparisons
were significant except between the two groups with the
greatest severity (Table 4 and Figure 4).
Discussion
This study estimated generic health utilities in a sample
of Spanish COPD patients according to different severity
classifications and by clinical phenotype. Irrespective of
the classification studied, an association between utilities
and disease severity was found, as the health utility of
COPD patients decreased as disease severity progressed
to more severe states and disease-related symptoms ap-
peared. The primary objective of the study was based on
Table 1 Characteristics of the study population
Characteristic Statistics N
Age (years), mean (SD) 67.9 (9.7) 346
Male, n (%) 296 (85.5%) 346
Smoker, n (%) 68 (19.7%) 346
Former smoker, n (%) 278 (80.3%)
Pack-years1, mean (SD) 54.2 (33.2) 346
Time from diagnosis (years), mean (SD) 7.6 (5.8) 346
BMI (kg/m2), mean (SD) 28.0 (5.4) 346
Lung function (post-bronchodilator),
mean (SD)
346
FVC (ml) 2619.3 (781.8)
FVC (%) 72.5 (18.7)
FEV1 (ml) 1272.1 (506.0)
FEV1 (%) 46.2 (15.5)
FEV1/FVC (%) 48.5 (11.6)
Positive post-bronchodilator test, n (%) 41 (15.9%) 258
Comorbidities (the most prevalent), n (%) 346
Cardiovascular disease2 94 (27.17%)
Diabetes2 57 (16.47%)
Malignant neoplasias 43 (12.43%)
Charlson index, mean (SD) 1.0 (1.4) 346
At least one exacerbation previous year, n (%) 202 (58.4%) 346
Exacerbations in the previous year, mean (SD) 1.3 (1.5) 346
At least one admission in previous year, n (%) 62 (17.9%) 346
Admissions previous year, mean (SD) 0.3 (0.6) 346
CAT total score3, mean (SD) 16.2 (7.8) 346
Impact in CAT, n (%) 346
Mild (0–10) 74 (21.4%)
Moderate (10–20) 163 (47.1%)
Severe (20–30) 87 (25.1%)
Very-severe (30–40) 22 (6.4%)
mMRC total score4 1.8 (1.1) 346
Impact in mMRC, n (%) 346
0 26 (7.5%)
1 129 (37.3%)
2 95 (27.5%)
3 69 (19.9%)
4 27 (7.8%)
BODEx index, mean (SD) 2.9 (1.9) 346
BODEx index classification, n (%) 346
0-2 167 (48.3%)
3-4 93 (26.9%)
Table 1 Characteristics of the study population
(Continued)
5-6 75 (21.7%)
7-9 11 (3.2%)
1Number of pack years = (packs smoked per day) × (years as a smoker).
2Cardiovascular diseases are myocardial infarction, congestive heart failure,
peripheral vascular disease and cerebrovascular disease. Diabetes means mild
or moderate diabetes and diabetes with chronic complications.
3Range of CAT total score is 0–40.
4Range of mMRC total score is 0–4.
SD = standard deviation, IQR = interquartile range, BMI = body mass index.
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function impairment [4]. However, the study also incor-
porated current recommendations on patient stratifica-
tion [5,6] being, up to our knowledge, the first study to
assess health utilities using these recent classifications.
The results obtained for the primary objective are con-
sistent with those found in other European studies. A re-
view of studies of HRQL measurements using the EQ-5D
questionnaire in COPD patients found mean (95% CI)
health utilities of 0.74 (0.66, 0.83) in moderate COPD,
0.69 (0.60, 0.78) in severe COPD and 0.61 (0.44, 0.77) in
very-severe COPD [12]. The health utilities estimated in
the present study were within the confidence intervals
presented above.
In Spain, a number of studies have estimated the util-
ity of COPD patients using the EQ-5D questionnaire.
The results of the present study were similar to those
obtained in a cohort of 115 mild-to-severe COPD pa-
tients, 0.72 (SD = 0.31) [29]. The INSEPOC study in-
cluded 4,574 COPD patients, irrespective of disease
severity, with a mean utility of 0.69 (SD = 0.28) [16]. In
the cross-sectional observational EPISCAN study [2] the
mean utility of 335 COPD patients was 0.86 (0.81, 0.91)
somewhat higher than our results, since this was a
population-based epidemiological study and most pa-
tients were newly diagnosed with mild disease.
Generic questionnaires are suggested to limit discrim-
inatory ability and some studies found little difference in
utilities in milder stages of COPD (mild vs moderate and
moderate vs severe) [11,30]. In the present study, the
sample size was powered to detect differences between
the three severity stages and significant differences in
utilities were found.
Even though the sample size was calculated to show
differences in the primary objective, differences were
also found according to GOLD 2013 classification, clin-
ical phenotypes and BODEx index. With respect to
GOLD 2013 classification, the three analyses performed
(classifying symptoms using CAT and mMRC, only CAT
and only mMRC) found statistical differences between
patients with fewer or more symptoms (groups A vs B and
C vs D). However, in the analysis performed using only
mMRC, no significant differences were found between
Table 2 GOLD 2013, clinical phenotypes and BODEx index by GOLD 2007 classification
GOLD 20071
Moderate n (%) Severe n (%) Very-severe n (%)
GOLD 20132 A 28 (20.7%) 0 (0.0%) 0 (0.0%)
B 66 (48.9%) 0 (0.0%) 0 (0.0%)
C 6 (4.4%) 22 (15.2%) 2 (3.0%)
D 35 (25.9%) 123 (84.8%) 64 (97.0%)
Clinical phenotype (GesEPOC) Non exacerbator 86 (68.8%) 88 (64.2%) 33 (55.0%)
COPD-asthma overlap 13 (10.4%) 7 (5.1%) 1 (1.7%)
Exacerbator with emphysema 9 (7.2%) 18 (13.1%) 14 (23.3%)
Exacerbator with chronic bronchitis 17 (13.6%) 24 (17.5%) 12 (20.0%)
BODEx index classification 0-2 124 (91.9%) 43 (29.7%) 0 (0.0%)
3-4 9 (6.7%) 72 (49.7%) 12 (18.2%)
5-6 2 (1.5%) 27 (18.6%) 46 (69.7%)
7-9 0 (0.0%) 3 (2.1%) 8 (12.1%)
1COPD moderate: FEV1/FVC < 0.70 and 50% ≤ FEV1 < 80%*, COPD severe: FEV1/FVC < 0.70 and 30% ≤ FEV1 < 50%*, COPD very-severe: FEV1/FVC < 0.70 y FEV1 < 30%*.
*respect to the reference value.
2A: low risk, few symptoms; B: low risk, many symptoms; C: high risk, few symptoms; D: high risk, many symptoms.
Table 3 EQ-5D-3 L quality of life questionnaire and utility
values
EQ-5D-3 L n (%) N
Mobility 346
No problems 160 (46.2%)
Some problems 184 (53.2%)
Extreme problems 2 (0.6%)
Self-care
No problems 246 (71.1%)
Some problems 83 (24.0%)
Extreme problems 17 (4.9%)
Usual activities
No problems 201 (58.1%)
Some problems 123 (35.5%)
Extreme problems 22 (6.4%)
Pain/discomfort
No problems 241 (69.7%)
Some problems 97 (28.0%)
Extreme problems 8 (2.3%)
Anxiety/depression
No problems 199 (57.5%)
Some problems 115 (33.2%)
Extreme problems 32 (9.2%)
Mean (SD) Median (IQR) N
Overall health status (range 1–15) 7.2 (2.0) 7.0 (2.0) 346
VAS (range 1–100) 59.1 (18.5) 60.0 (20.0) 345
Utility values 0.73 (0.29) 0.81 (0.26) 346
SD = standard deviation, IQR = interquartile range, VAS = visual analogic scale.
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and in the two other analyses differences were found be-
tween B and D but not between A and C. These results
might suggest that symptoms are better predictors of util-
ities than lung function or exacerbations. Further studies
would be needed to confirm this hypothesis. While the
distribution of patients varied in the three GOLD 2013
analyses, the results obtained by evaluating the symptoms
using CAT and mMRC were very similar to those ob-
tained using only CAT. However, when only mMRC was
considered, the distribution of patients was different to
that obtained with the other two analyses, resulting in an
estimate of health utilities that also differed. A recent
study [31] found a weak association between CAT and
mMRC, corroborating these results.
With respect to GesEPOC phenotype classification,
significant differences were found between exacerbators
and non-exacerbators, corroborating the importance of
exacerbations in HRQL. The EPISCAN study estimated
the mean utility of COPD-asthma overlap patients (0.76),
showing significant differences with non-overlap patients
[18]. The present study found not statistically significant
differences in mean utility values (0.81 for COPD-asthma
overlap, and 0.72 for non-overlap phenotypes, p = 0.07),
probably due to a lack of statistical power.
There are no published studies that evaluate the asso-
ciation between BODEx index and utility. However, the
analyses performed on the BODE index [32-34] con-
cluded that HRQL deteriorated as the severity of COPD
increased. These results are consistent with the results
of the present study.
The percentage of patients with the highest-possible
utility (value 1) was 22% (moderate COPD 29.6%, severe
Table 4 Utility estimates by GOLD 2007, GOLD 2013, clinical phenotypes and BODEx index classification
Utilities p1
n (%) Mean (SD) Median (IQR)
GOLD 20072 COPD moderate 135 (39.0%) 0.82 (0.22) 0.87 (0.22) <0.001
COPD severe 145 (41.9%) 0.72 (0.29) 0.80 (0.26)
COPD very-severe 66 (19.1%) 0.57 (0.35) 0.66 (0.42)
GOLD 20133 A 28 (8.1%) 0.96 (0.07) 1.00 (0.09) <0.001
B 66 (19.1%) 0.80 (0.22) 0.87 (0.13)
C 30 (8.7%) 0.88 (0.25) 1.00 (0.16)
D 222 (64.2%) 0.66 (0.31) 0.74 (0.29)
Clinical phenotype (GesEPOC) Non exacerbator 207 (64.3%) 0.79 (0.24) 0.84 (0.33) <0.001
COPD-asthma overlap 21 (6.5%) 0.81 (0.20) 0.80 (0.26)
Exacerbator with emphysema 41 (12.7%) 0.56 (0.42) 0.71 (0.62)
Exacerbator with chronic bronchitis 53 (16.5%) 0.59 (0.36) 0.72 (0.57)
BODEx index classification 0-2 167 (48.3%) 0.85 (0.18) 0.89 (0.20) <0.001
3-4 93 (26.9%) 0.69 (0.29) 0.80 (0.27)
5-6 75 (21.7%) 0.56 (0.35) 0.67 (0.29)
7-9 11 (3.2%) 0.33 (0.30) 0.41 (0.31)
1Kruskal-Wallis test and Mann–Whitney U test for post-hoc comparisons (Bonferroni-adjusted). Unilateral tests for pulmonary function, GesEPOC and BODEx index.
GOLD 2007: all pairwise comparisons were significant; GOLD 2013: all pairwise comparisons were significant, except for the comparison between groups A and C;
Clinical phenotypes: differences between phenotypes A and C, A and D, and between B and D; BODEx index classification: all pairwise comparisons were
significant except between the two groups with the greatest severity.
2COPD moderate: FEV1/FVC < 0.70 and 50% ≤ FEV1 < 80%*, COPD severe: FEV1/FVC < 0.70 and 30%≤ FEV1 < 50%*, COPD very-severe: FEV1/FVC < 0.70 y FEV1 < 30%*.
*respect to the reference value.
3A: low risk, few symptoms; B: low risk, many symptoms; C: high risk, few symptoms; D: high risk, many symptoms.
SD = standard deviation, IQR = interquartile range.
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http://www.hqlo.com/content/12/1/120COPD 20%, very-severe COPD 10.6%), evidencing a ceil-
ing effect, which was also observed in previous studies
[12,13,20,27]. One of these studies [13] evaluated EQ-5D
questionnaire in 1,235 COPD patients from 13 countries
and found that 22.9% patients obtained the highestFigure 1 Utility estimates by GOLD 2007 classification. LEGEND:
Graph shows utilities≥ 0.health utilities (moderate COPD 27.8%, severe COPD
19.7%, very-severe COPD 4.4%). The higher percentage
of patients with the highest utility in the very-severe
group found in the present study might be due to
within-group variability, which is higher than in theFigure 2 Utility estimates by GOLD 2013 classification. LEGEND:
A: low risk, fewer symptoms; B: low risk, more symptoms; C: high risk,
fewer symptoms, D: high risk, more symptoms. Graph shows utilities≥ 0.
Table 5 Sensitivity analysis of utility estimates by GOLD 2013 classification
Base case Sensitivity analyses
CAT and mMRC CAT mMRC p-value3
GOLD 20132
A
0.058
N (%) 28 (8.1%) 33 (9.5%) 68 (19.7%)
Mean (SD) 0.96 (0.07) 0.94 (0.10) 0.91 (0.09)
Median (IQR) 1.00 (0.09) 1.00 (0.09) 0.91 (0.16)
B
0.04
N (%) 66 (19.1%) 61 (17.6%) 26 (7.5%)
Mean (SD) 0.80 (0.22) 0.80 (0.23) 0.68 (0.30)
Median (IQR) 0.87 (0.13) 0.87 (0.13) 0.78 (0.35)
C
0.2
N (%) 30 (8.7%) 41 (11.8%) 87 (25.1%)
Mean (SD) 0.88 (0.25) 0.86 (0.24) 0.84 (0.22)
Median (IQR) 1.00 (0.16) 0.91 (0.18) 0.89 (0.22)
D
0.1
N (%) 222 (64.2%) 211 (61.0%) 165 (47.7%)
Mean (SD) 0.66 (0.31) 0.65 (0.31) 0.61 (0.32)
Median (IQR) 0.74 (0.29) 0.74 (0.31) 0.71 (0.31)
p value1 <0.001 <0.001 <0.001
1Kruskal-Wallis test and Mann-Whitney U test for post-hoc comparisons (Bonferroni-adjusted).
Base case and sensitivity analysis (CAT): all pairwise comparisons were significant except between A and C; Sensitivity analysis (mMRC): all pairwise comparisons
were significant except between A and C, and between B and D.
2A: low risk, few symptoms; B: low risk, many symptoms; C: high risk, few symptoms; D: high risk, many symptoms.
3Comparison of utilities according to classification by CAT or mMRC. Mann-Whitney U test (without alpha-adjustment).
SD = standard deviation, IQR = interquartile range, CAT = COPD Assessment Test, mMRC = modified Medical Research Council.
Figure 3 Utility estimates by GesEPOC clinical phenotypes.
LEGEND: Graph shows utilities≥ 0.
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http://www.hqlo.com/content/12/1/120other severity groups due to the lower number of very-
severe COPD patients.
Generic utilities constitute an essential parameter in
health economic evaluations. Most of the published CU
analysis in COPD based disease progression on lungFigure 4 Utility estimates by BODEx index classification.
LEGEND: Graph shows utilities≥ 0.
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http://www.hqlo.com/content/12/1/120function decline, and therefore results of the primary ob-
jective could be used to populate future economic ana-
lyses. However, due to the multifactorial nature of COPD,
utility values estimated in the secondary objectives of this
study provide new evidence for the development of new
economic models that base disease progression on other
clinical variables besides lung function. According to the
results of the study, it seems that the GOLD 2007 guide-
lines and the BODEx index better discriminate patients
who have a worse health status than the GOLD 2013
guidelines. At the same time, the GOLD 2013 guidelines
are better able to identify a smaller group of patients
(GOLD A) with the best health. This may have implica-
tions on future economic evaluations of COPD, which
could consider different disease severity classifications de-
pending on the main focus of the study. For instance, if
the main interest of the economic evaluation is severe or
very-severe COPD patients, the GOLD 2007 guidelines
might be preferable as they differentiate the health status
of these patients better than the GOLD 2013 guidelines.
In contrast, the GOLD 2013 guidelines might be preferred
in studies whose main focus is on COPD patients with the
best health.
The main limitations of the study are related to the
sample selection. Firstly, due to the low prevalence of
patients with very-severe stable COPD, the number of
patients recruited in this category was lower than for the
other levels of severity. This may limit the external valid-
ity of the results. The sample calculation was, however,
sufficient to allow detecting differences between severity
levels, and comparison with other studies supports the
consistency of the results. On the other hand, due to
methodological requirements for utility estimates, pa-
tients needed to be stable with no exacerbation in the
previous two months. This could have biased the inclu-
sion of GOLD A and B patients and GesEPOC pheno-
type non exacerbators, and the distribution of patients
in the study could differ from the real prevalence. Never-
theless, all groups were sufficiently well-represented in
the study to estimate utilities. Finally, 85.5% of the pa-
tients enrolled were male. Although this is consistent
with the epidemiology of COPD in Spain, the results
should be interpreted with caution when extrapolated to
females.
Conclusion
This observational cross-sectional study found an associ-
ation between generic utilities and all clinical variables
used for disease classification (airflow limitation, exacerba-
tion history, symptoms, clinical phenotypes and BODEx
index), as the health utility of COPD patients decreased as
disease severity progressed to more severe states and
disease-related symptoms appeared. GOLD 2007 guide-
lines and BODEx index better discriminated patients witha worse health status than the GOLD 2013 guidelines,
while GOLD 2013 guidelines were better able to identify a
smaller group of patients with the best health. Estimated
generic utilities for the different COPD stages may be ap-
propriate to model health outcomes in economic evalua-
tions of COPD treatments.
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